media – Page 13 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Glaukos Corporation to receive Pre-Market approval for Next-Gen iStent

The inject is developed to achieve the natural outflow of aqueous humor by making two patent bypasses through the trabecular meshwork, glaucomatous eyes the main source of resistance resulting in multi-directional flow through Schlemm’s canal
- Source: BioSpectrumAsia
- 130
- June 26, 2018
FDA medtech New Approvals Optometry
What are the Impacts of Multiple Stents?

A shocking report revealed that patients with multiple stents or having longer stent greater than 31.5mm could be associated with high risk of mortality. Around 4.5% of patients died within a year of angioplasty. Death occurred in patients between the age group 35-75, where most of the people were elderly. Similarly, more patients who received metal stents had to be re-hospitalized, compared to those who received sophisticated drug-eluting stents.
- Source: India Times
- 161
- June 26, 2018
coronary stent medical device Researches
Overuse of Multivitamins could be Harmful

Usage of multivitamins either through prescription or on own accord possibly crossed a limit in the past few years. New research published in Journal of American College of Cardiology reveals that health supplements can increase the risk of heart issues.
- Source: India Times
- 179
- June 26, 2018
Researches vitamin
Call for HIMSS19 Global Conference Speaker Proposals

There will be a total of twenty-four education categories/topics, which includes five new topics namely consumerization of health, grand societal challenges, healthy aging and technology, population and public health management as well as supply chain management.
- Source: MobiHealthNews
- 138
- June 26, 2018
Company Insight digital health health IT HIMSS
FDA Anounces Restricted use of Keytruda & Tecentriq Against Bladder Cancer

Keytruda is now allowed only for the patients whose tumor expression levels of the biomarker PD-L1 meet a combined positive score of 10 or higher. Tecentriq can only be used where PD-L1 immune cells can cover only 5% or more of their tumor area.
- Source: FiercePharma
- 158
- June 26, 2018
bladder cancer Company Insights Merck Roche
Nanobiotix NBTXR3 in Late Phase Clinical Trial

NBTXR3 is composed of crystalline nanoparticles to amplify the efficacy of radiation therapy. The idea is to administer NBTXR3 as intra-tumoral injections before external beam radiation therapy, thereby increasing the antitumor effect, and thus preparing the patient for surgical resection.
- Source: FierceBiotech
- 149
- June 26, 2018
cancer Clinical Trials radiation therapy
AstraZeneca’s Durvalumab Receives Go-Ahead from DCGI to Market in India

Last Friday, pharma giant AstraZeneca announced that it had received the go-ahead from the Drug Controller General of India (DCGI) to import and market durvalumab (ImfinziTM) in India. The receipt of this permission paves the way for the launch of durvalumab (ImfinziTM) in India. Durvalumab which is a patented drug of Astra-Zeneca, received permission in India to provide treatment for patients with unresectable non-small cell lung cancer and metastatic urothelial carcinoma.
- Source: United News of India
- 1,977
- June 26, 2018
AstraZeneca cancer India New Approvals
India’s First Future Health Index Launched by Philips

Key findings of the FHI 2018 allude to the lack of access on account of low skilled physician density and a low number of hospital beds. The study also highlighted the fact that semi-urban and rural areas are yet to leverage the advancements of digital healthcare. It also stated that healthcare professionals in the country were open to the deployment of futuristic technology such as AI and virtual reality in healthcare as compared to the general population.
- Source: Economic times
- 186
- June 25, 2018
Future Health Index India Market Views Phillips
Autolus Raises Impressive $150 Million for T-cell Therapy

The IPO has provided the biotech major with the financial bandwidth to aggressively pursue its new generation of CAR-T variants on a broader level, with the advancement of several therapies or the start of clinical trials over the next couple of months.
- Source: FierceBiotech
- 135
- June 25, 2018
acquisition cancer CAR-T therapies Company Insight
Cotiviti Holdings Acquired by Verscend Technologies for $4.9 Billion

The new business with unique data-driven capabilities will work as a private healthcare IT company with a big impact in the health sector by reducing waste and improving quality outcomes and affordability as well as offering opportunities to create substantial value for clients.
- Source: Healthcare Global
- 132
- June 25, 2018
Company Insight health IT

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

Exhibitions & Activitiesmore

Ddu to Attend CPhI in Shanghai Sharing Insights on International Marketing of the Medical Trade

June 19, 2018
IRANPHARMA EXPO 2018

June 14, 2018
Drugdu.com Launches Digital Marketing Strategy Solution for Pharmaceuticals and Medical Devices at CMEF Shanghai 2018

May 8, 2018
Ddu Attended CPhI North America Great Success with the “Internet + Cross-border medical trade” Marketing Model

May 3, 2018
Ddu’s International Medical Exhibition Attendance Delivering High Results.

April 9, 2018

Market Reportsmore

China’s Import and Export Market Report of Diabetes Drugs

May 4, 2018
China’s Import and Export Market Report of Vitamins

April 11, 2018
China’s Import and Export Market Report of Contraceptive Drugs

March 16, 2018
Ddu College — China’s Import and Export Report of Peptic Ulcer Drugs

January 25, 2018
China’s Import and Export Report of External Use Otology Drugs

January 12, 2018

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.